1	STATE OF OKLAHOMA	
2	2nd Session of the 56th Legislature (2018)	
3	HOUSE BILL 2565 By: Ford (Ross)	
4		
5		
6	AS INTRODUCED	
7	An Act relating to controlled dangerous substances; amending 63 O.S. 2011, Section 2-309, as last amended	
8	by Section 1, Chapter 323, O.S.L. 2013 (63 O.S. Supp. 2017, Section 2-309), which relates to the Uniform Controlled Dangerous Substances Act; requiring electronic prescribing for all scheduled drugs;	
9		
10	providing exceptions; modifying certain definition; and providing an effective date.	
11		
12		
13	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:	
14	SECTION 1. AMENDATORY 63 O.S. 2011, Section 2-309, as	
15	last amended by Section 1, Chapter 323, O.S.L. 2013 (63 O.S. Supp.	
16	2017, Section 2-309), is amended to read as follows:	
17	Section 2-309. A. 1. Except for dosages medically required	
18	for a period not to exceed forty-eight (48) hours which are	
19	administered by or on direction of a practitioner, other than a	
20	pharmacist, or medication dispensed directly by a practitioner,	
21	other than a pharmacist, to an ultimate user, no controlled	
22	dangerous substance included in Schedule II, which is a prescription	
23	drug as determined under regulation promulgated by the Board of	
24	Pharmacy, may shall be dispensed without the written an electronic	

prescription of a practitioner; provided, that in emergency
situations, as prescribed by the Board of Pharmacy by regulation,
such drug may be dispensed upon oral prescription reduced promptly
to writing and filed by the pharmacist in a manner to be prescribed
by rules and regulations of the Director of the Oklahoma State
Bureau of Narcotics and Dangerous Drugs Control.

2. Electronic prescribing $\frac{\text{may}}{\text{may}}$ shall be utilized for Schedules II, III, IV, and V, subject to the requirements set forth in 21 CFR, Section 1311 et seq.

1.3

2.1

- 3. The transmission of written prescription by practitioner to dispensing pharmacy by facsimile or electronic transmission with electronic signature is permitted only under the following conditions:
 - a. for Schedule II drugs, the original prescription must be presented and verified against the facsimile at the time the substances are actually dispensed, and the original document must be properly annotated and retained for filing, except:
 - to be a "written prescription" as required by

 Section 2-101 et seq. of this title and as

 required by Title 21 U.S.C., Section 829(a). The

 facsimile copy of the prescription shall be

 retained as an original prescription, and it must

contain all the information required by Section 2-101 et seq. of this title and 21 CFR, Section 1306.05(a), including date issued, the patient's full name and address, and the practitioner's name, address, DEA registration number, and signature. The exception to the regulations for home infusion/IV therapy is intended to facilitate the means by which home infusion pharmacies obtain prescriptions for patients requiring the frequently modified parenteral controlled release administration of narcotic substances, but does not extend to the dispensing of oral dosage units of controlled substances,

- (2) the same exception is granted to patients in Long

 Term Care facilities (LTCF), which are filled by

 and delivered to the facility by a dispensing

 pharmacy, and
- (3) an An electronic prescription with electronic signature may serve as an original prescription, subject to the requirements set forth in 21 CFR, Section 1311 et seq., and
- b. for drugs in Schedules III and IV, a facsimile copy of a written, signed prescription transmitted directly by the prescribing practitioner to the pharmacy can serve

1		as an original pre
2		may be utilized fo
3		the same requireme
4		1311 et seq.
5	4. <u>3.</u> Pr	escriptions shall b
6	requirements	of this section and
7	prescription	for a Schedule II s
8	4. The e	lectronic prescript
9	section shall	not apply to presc
10	substances is	sued by any of the
11	<u>a.</u>	a person licensed
12	<u>b.</u>	a practitioner who
13		or electrical fail
14		circumstance that
15		transmitted electr
16		the practitioner d
17		exception in the m
18	<u>C.</u>	a practitioner, ot
19		directly to an ult
20	<u>d.</u>	a practitioner who
21		substance to be ad
22		home, hospice faci

23

24

as an original prescription. Electronic prescribing

may be utilized for Schedules III and IV subject to

the same requirements as set forth in 21 CFR, Section

- $4. \ 3.$ Prescriptions shall be retained in conformity with the requirements of this section and Section 2-307 of this title. No prescription for a Schedule II substance may be refilled.
- 4. The electronic prescription requirement provided for in this section shall not apply to prescriptions for controlled dangerous substances issued by any of the following:
 - a. a person licensed to practice veterinary medicine,
 - b. a practitioner who experiences temporary technological or electrical failure or other extenuating circumstance that prevents the prescription from being transmitted electronically; provided, however, that the practitioner documents the reason for this exception in the medical record of the patient,
 - a practitioner, other than a pharmacist, who dispenses directly to an ultimate user,
 - a practitioner who orders a controlled dangerous substance to be administered in a hospital, nursing home, hospice facility, outpatient dialysis facility or residential care facility,

e. a practitioner who writes a prescription to be

dispensed by a pharmacy located on federal property;

provided, however, that the practitioner documents the reason for this exception in the medical record of the patient, or

- <u>a practitioner or health care facility that does not</u>
 <u>have Internet access or an electronic health record</u>
 <u>system.</u>
- B. 1. Except for dosages medically required for a period not to exceed forty-eight (48) hours which are administered by or on direction of a practitioner, other than a pharmacist, or medication dispensed directly by a practitioner, other than a pharmacist, to an ultimate user, no controlled dangerous substance included in Schedule III or IV, which is a prescription drug as determined under regulation promulgated by the Board of Pharmacy, may shall be dispensed without a written or oral an electronic prescription.
- 2. A written or oral An electronic prescription for a controlled dangerous substance in Schedule III or IV may not be filled or refilled more than six (6) months after the date thereof or be refilled more than five times after the date of the prescription, unless renewed by the practitioner.
- 3. A written or oral An electronic prescription for any product containing hydrocodone with another active ingredient shall not be refilled.

C. No controlled dangerous substance included in Schedule V may be distributed or dispensed other than for a legitimate medical or scientific purpose.

- D. Except for dosages medically required for a period not to exceed forty-eight (48) hours which are administered by or on direction of a practitioner, other than a pharmacist, or medication dispensed directly by a practitioner, other than a pharmacist, to an ultimate user, tincture opium camphorated, commonly known as paregoric, may not be dispensed without a written or oral an electronic prescription. The refilling of a prescription for paregoric shall be unlawful unless permission is granted by the prescriber, either written or oral pursuant to an electronic prescription.
- E. Whenever it appears to the Director that a drug not considered to be a prescription drug under existing state law or regulation of the Board of Pharmacy should be so considered because of its abuse potential, the Director shall so advise the Board of Pharmacy and furnish to the Board all available data relevant thereto.
- F. "Prescription", as used herein, means a written er, oral or electronic order by a practitioner to a pharmacist for a controlled dangerous substance for a particular patient, which specifies the date of its issue, and the full name and address of the patient; if the controlled dangerous substance is prescribed for an animal, the

```
species of the animal; the name and quantity of the controlled
dangerous substance prescribed; the directions for use; the name and
address of the owner of the animal and, if written, the signature of
the practitioner.
```

G. No person shall solicit, dispense, receive or deliver any controlled dangerous substance through the mail, unless the ultimate user is personally known to the practitioner and circumstances clearly indicate such method of delivery is in the best interest of the health and welfare of the ultimate user.

SECTION 2. This act shall become effective November 1, 2018.

12 56-2-9237 12/27/17

GRS

1.3 14

1

2

3

4

5

6

7

8

9

10

11

15

16

17

18

19

20 21

22

23

24